Tag Archives: Healthcare IT

Global Funding Insights for Digital Health Initiatives in 2018

12 Jul

By Ashley Durrer, Marketing Manager, LSN

This week I interviewed Colin Widen, the CEO of Boston Innovation Capital (BIC), Life Science Nation’s (LSN) wholly-owned broker-dealer arm, to learn where investors are allocating funds, and the current focus on healthcare advancement within the digital health space.

BIC works alongside LSN and our network of investors to support early-stage companies in forging connections with investors, major pharma firms, and other strategic players in the life science world. By managing clients’ fundraising campaigns and connecting them to investors who are a good fit, BIC is able to address its, and LSN’s, mission of advancing new and innovative technologies to the clinic.

Interview with Colin Widen moderated by Ashley Durrer

AD: With billions of dollars being poured into digital health, why the sudden increase?

CW: “Healthcare needs to find a way to pay for digital health now that value-based care and hospital incentives are aligned to support lower costs in healthcare with improved patient care. There are new potentials for change within the telemedicine space in light of ongoing healthcare reforms and debate.”

AD: How will that turn out for those seeking funding?

CW: “Digital health initiatives will be the least impacted by changes to the American healthcare system, making them prime opportunities for investment this year.

“There is a much lower cost to creating software, virtual platforms, compliance tools, etc. than creating advances in biologics, drugs, and other life science advancements, making digital health an increasingly popular space for investors. Successfully investing in therapeutics or medical devices requires a great deal of expertise, not to mention the increased risk due to the potential failure in clinical trials. On the other hand, software is a recognizable, lower cost, and scalable business model that is often also easily adaptable when regulations change.”

AD: Where does BIC fit into global funding from client perspectives?

CW: “BIC is working tirelessly to support digital health technologies that will have a real impact on the healthcare system for our doctors, nurses, and hospitals. This year BIC is focused on digital health technologies, assets, and virtual tools, which can support doctors’, hospitals’, and nurses’ efforts with patients. However, this currently excludes consumer-based products and electronic medical record (EMR) initiatives.”

AD: What are some examples of potential best-fit clients?

CW: “Some examples recognized in the market are pill dispensers and medicinal tracking for patient compliance, health portals for patients and doctors, mental health apps, medication tracking, patient monitoring and more.”

AD: What kind of client are you seeking now? Can you share a potential client profile?

CW: “Within our LSN network of investors, feedback clearly shows there is an increasing appetite to invest in niche digital health opportunities.

“Investors are seeking companies within the top-tier of their specialization, and a proven business model within the market. Often these investors want to see that the product, software, tool, etc. are viable, which means it’s already being used within the market e.g. hospitals. This also includes an accompanying value proposition for payors and the company is receiving ongoing revenue for that service.”

BIC Global Network of Digital Health Investors are focused on:

  • Funding of $10M-50M
  • Min $3mm+ ARR
  • Niche companies within the top-tier of their specialization
  • Currently avoiding pure EMR focused and consumer-based products

The Future of Digital Health

There are innovations happening every day to help improve access to healthcare. 2018 has already seen an increase in the debate over healthcare reform, rising insurance costs, and uncertainty of coverage for millions of Americans. Advancements in technologies and virtual tools for doctors and hospitals could really help to streamline processes and reduce overall costs for themselves as well as the patients they serve.

We can’t wait to hear what new innovations are entering the digital health space.

About Colin Widen, CEO

Colin Widen, registered representative, is a seasoned executive with 25 years of sales, trading and portfolio management experience in major investment banks. Colin joined Deutsche Bank where he led a team providing consulting services about alternative asset allocation strategies to family offices and smaller endowments and foundations. In creating BIC, Colin has combined investment skills with the robust investor network of LSN to offer a unique platform. Colin is a registered representative and holds Series 7, 24, 63 and 82 registrations. His specialties include reconstructing hedge fund portfolios. analyzing private equity holdings and helping with strategy and execution of capital raise initiatives across the spectrum of today’s life science assets.

About Boston Innovation Capital

Boston Innovation Capital (BIC), a wholly owned subsidiary of Life Science Nation Holdings, became a FINRA-registered broker-dealer in 2016. BIC works alongside LSN’s other two divisions (LSN’s Investor Platform and Company Platform, and the RESI Conference Group) to support early-stage companies in forging connections with investors, major pharma firms and other strategic players in the life science world.

Hot Investor Mandate: Singapore-Based PE Firm Invests Up to $20M in All Areas of Life Sciences with Potential for Global Growth, Open to Any Stage of Development

12 Jul

A private equity and corporate finance advisory firm is headquartered in Singapore with a global presence. The firm makes global investments into life science and healthcare companies as well as services related to healthcare. The firm acts as a lead investor and utilizes their network to seek out other co-investors. Typical deal size is $0.5m to $20m. The firm will occasionally seek distribution rights for international investments.

The firm is interested in therapeutics, medical devices, diagnostics, healthcare IT, healthcare services, biotech, R&D services and suppliers and engineering companies. The firm is both stage and indication agnostic and has no revenue requirement. The firm has no flexible investment criteria but the East West Axis is very important as the firm is not interested in companies that are restricted to one country. The firm looks for companies with a multinational, global component.

The firm is flexible with their management team requirements. The firm is open to bringing in their own talent to assist with management and have supported scientists in becoming successful entrepreneurs. The firm is a value-added investor driven by opportunity. The firm takes a board seat when making investments.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate 3: USA VC Firm Seeks to Invest in All Sectors of Life Sciences, with Focus on Companies Outside of Major Biotech Hubs

3 May

A venture capital firm based in Texas is focused on early and growth-stage biotech and medical device companies. The group is currently raising their second fund and is actively evaluating deals. Initial investments typically are in the $3M-$5M range and are usually in the form of straight equity, but may use convertible notes in select situations. The firm looks to take meaningful stake in portfolio companies and play an active role in their development. The firm is open to companies based in the U.S., with a specific interest in companies located outside of the major biotech hubs of Boston and San Francisco.

The firm is most interested in the biotech/therapeutics space and will consider medtech companies on a secondary basis. The firm does not invest in diagnostic or healthcare IT companies. The firm is mostly opportunistic in terms of technology type and indication area, however the group prioritizes companies with products addressing unmet medical need and unique mechanisms of action. For early-stage companies, the firm targets companies who have at least had a pre-IND meeting with the FDA and invest in companies ranging from pre-clinical to Ph. II clinical trials.

The firm has no strict company or management team requirements, but does look to be a very active investor and always requires a board seat along with an investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

%d bloggers like this: